Safety and Efficacy of Miglustat in Chinese NPC Patients

A Single Arm Uncontrolled 12 Months Clinical Study to Evaluate the Safety and Efficacy of Miglustat (Zavesca) for the Treatment of Niemann Pick Type C Disease (NPC) in Chinese Subjects

This is a prospective, multi-center, open-label, non-randomized, single-arm Phase IV confirmatory study.

Approximately 19 subjects with Niemann Pick Type C disease (NPC) will be enrolled in this study. The study will be conducted at 2 sites in China.

Study Overview

• Status: Completed
• Conditions: Niemann-Pick Disease, Type C
• Intervention / Treatment: Drug: Miglustat

Detailed Description

This is a prospective, multi-center, open-label, non-randomized, single-arm Phase IV confirmatory study.The study is conducted in Chinese subjects aged 4 years and older with Niemann Pick Type C disease (NPC). Approximately 19 subjects will be enrolled in this study. The study will be conducted at 2 sites in China. Patients will be treated with miglustat for 12 months, efficacy and safety outcomes will be measured

• Study Type: Interventional
• Enrollment (Actual): 17
• Phase: Phase 4

Contacts and Locations

Study Locations

• China
  • Beijing, China, 100034
    • Peking University First Hospital
  • Shanghai, China, 200092
    • Xin Hua Hospital, Shanghai Jiao Tong University

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 2 years and older (Child, Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria:

• Patients with confirmed 2 pathogenic mutations in either Niemann Pick Type C Gene 1 or 2 (NPC 1 or NPC 2) or 1 pathogenic mutation in either NPC1 or NPC2 plus a positive biomarker (oxysterol or lysosphingolipids or bile acids) plus high clinical suspicion
• Signed informed consent prior to any study-mandated procedure.
• For subjects who are younger than 18 years consent must be sought of at least one legal guardian who shall sign the informed consent form and indicate the relationship between him/her and the subject.
• Subjects who are 18 years or older must sign the consent. If the subject cannot make an independent decision to participate in the study, consent must be sought of the legal agents who shall sign the informed consent form and indicate the relationship between him/her and the subject.
• Male and female subjects aged 4 years and older.
• Subjects who can performed the tests for the horizontal and vertical saccadic eye movements;
• Subjects who are able to swallow the study drug;
• Women of childbearing potential are only eligible if the following applies:
• Negative urine pregnancy test at screening.
• Agreement to undertake monthly urine pregnancy tests during the study and up to at least 30 days after study treatment discontinuation.
• Agreement to use one of the methods of birth control / follow the contraception scheme from screening up to at least 30 days after study treatment discontinuation.
• A fertile male (physiologically capable of fathering a child according to investigator's judgment) is eligible only if he agrees to use a condom during the treatment period and for an additional 12 weeks after treatment discontinuation.

Exclusion Criteria:

Subjects must not fulfill any of the following exclusion criteria. It is not permitted to waive any of the criteria for any subject:

• Subjects suffering from clinically significant diarrhea (>3 liquid stools per day for >7 days) without definable cause within 3 months before enrollment.
• Known hypersensitivity to the investigational treatment or drugs of the same class, or any of their excipients.
• Subjects who suffer from renal insufficiency with a creatinine clearance rate (CCR) of < 30ml/min per 1.73m2.
• Pregnant, planning to be become pregnant or lactating females, not using reliable birth control male adult subjects.
• Previous exposure to investigational treatment for more than 12 months before study start.
• Planned or current treatment with another investigational treatment up to 3 months prior to randomization. Symptomatic therapies are allowed (such as curcumin).
• Any known factor or disease that might interfere with treatment compliance, study conduct, or interpretation of the results, such as drug or alcohol dependence or psychiatric disease, end stage disease including wheelchair bound patients, bedridden patients etc.
• Subjects who are judged unqualified for the clinical trial by the investigator.
• Subjects who suffer lysosomal storage diseases, enzyme deficiency or neurological diseases other than NPC.
• Subjects who suffer variant filipin staining without confirmatory genetic diagnosis of NPC.
• Subjects with uncontrolled epilepsy.
• Subjects with complete ophthalmoplegia.
• Known concomitant life-threatening disease with a life expectancy < 12 months.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: N/A
• Interventional Model: Single Group Assignment
• Masking: None (Open Label)

Number of Arms

1

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: Miglustat; Miglustat is administered three times a day as an oral capsule	Drug: Miglustat; capsule, oral use

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Observed change in HSEM (ms/deg)	Change in HSEM from baseline to week 52	baseline to week 52

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Change in Pineda disability scale score	Change in the modified Pineda disability scale score. The scale is assessing 4 key domains (manipulation, ambulation, language and swallowing). Individual scores of the domains are claculated ted into a composite score, 6 being the lowest and best score and 24 being the worst and highest score.	baseline to week 52
Incidence of treatment-emergent AEs and SAEs	Treatment-emergent adverse events (AEs) up to 30 days after EOT	Baseline to 30 days after End of Treatment (Week 52)

Collaborators and Investigators

• Sponsor: Actelion
• Investigators: Study Director: Yue Wu, Janssen China R&D

Study record dates

Study Major Dates

• Study Start (Actual): April 2, 2020
• Primary Completion (Actual): March 25, 2022
• Study Completion (Actual): March 25, 2022

Study Registration Dates

• First Submitted: March 8, 2019
• First Submitted That Met QC Criteria: April 9, 2019
• First Posted (Actual): April 10, 2019

Study Record Updates

• Last Update Posted (Actual): May 25, 2022
• Last Update Submitted That Met QC Criteria: May 24, 2022
• Last Verified: May 1, 2022

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Mental Disorders; Metabolic Diseases; Brain Diseases; Central Nervous System Diseases; Nervous System Diseases; Lymphatic Diseases; Neurocognitive Disorders; Genetic Diseases, Inborn; Metabolism, Inborn Errors; Lysosomal Storage Diseases; Lipid Metabolism Disorders; Dementia; Brain Diseases, Metabolic; Brain Diseases, Metabolic, Inborn; Sphingolipidoses; Lysosomal Storage Diseases, Nervous System; Lipidoses; Lipid Metabolism, Inborn Errors; Frontotemporal Lobar Degeneration; Histiocytosis, Non-Langerhans-Cell; Histiocytosis; Frontotemporal Dementia; Pick Disease of the Brain; Niemann-Pick Diseases; Niemann-Pick Disease, Type A; Niemann-Pick Disease, Type C; Hypoglycemic Agents; Physiological Effects of Drugs; Molecular Mechanisms of Pharmacological Action; Anti-Infective Agents; Antiviral Agents; Enzyme Inhibitors; Anti-HIV Agents; Anti-Retroviral Agents; Glycoside Hydrolase Inhibitors; Miglustat
• Other Study ID Numbers: AC-056C405

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No